Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma

Author:

Ochoa-Rios Shaaron1ORCID,Blaschke Calvin R.K.1ORCID,Wang Mengjun1ORCID,Peterson Kendell D.2ORCID,DelaCourt Andrew1ORCID,Grauzam Stéphane Elie1ORCID,Lewin David3ORCID,Angel Peggi1ORCID,Roberts Lewis R.4ORCID,Drake Richard1ORCID,Mehta Anand S.1ORCID

Affiliation:

1. 1Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.

2. 2Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina.

3. 3Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.

4. 4Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Abstract

There is an urgent need for the identification of reliable prognostic biomarkers for patients with intrahepatic cholangiocarcinoma (iCCA) and alterations in N-glycosylation have demonstrated an immense potential to be used as diagnostic strategies for many cancers, including hepatocellular carcinoma (HCC). N-glycosylation is one of the most common post-translational modifications known to be altered based on the status of the cell. N-glycan structures on glycoproteins can be modified based on the addition or removal of specific N-glycan residues, some of which have been linked to liver diseases. However, little is known concerning the N-glycan alterations that are associated with iCCA. We characterized the N-glycan modifications quantitatively and qualitatively in three cohorts, consisting of two tissue cohorts: a discovery cohort (n = 104 cases) and a validation cohort (n = 75), and one independent serum cohort consisting of patients with iCCA, HCC, or benign chronic liver disease (n = 67). N-glycan analysis in situ was correlated to tumor regions annotated on histopathology and revealed that bisected fucosylated N-glycan structures were specific to iCCA tumor regions. These same N-glycan modifications were significantly upregulated in iCCA tissue and serum relative to HCC and bile duct disease, including primary sclerosing cholangitis (PSC) (P < 0.0001). N-glycan modifications identified in iCCA tissue and serum were used to generate an algorithm that could be used as a biomarker of iCCA. We demonstrate that this biomarker algorithm quadrupled the sensitivity (at 90% specificity) of iCCA detection as compared with carbohydrate antigen 19-9, the current “gold standard” biomarker of CCA.Significance:This work elucidates the N-glycan alterations that occur directly in iCCA tissue and utilizes this information to discover serum biomarkers that can be used for the noninvasive detection of iCCA.

Funder

HHS | National Institutes of Health

Publisher

American Association for Cancer Research (AACR)

Reference44 articles.

1. Diagnosis and management of cholangiocarcinoma;Sandhu;Curr Gastroenterol Rep,2008

2. Cholangiocarcinoma;Sarcognato;Pathologica,2021

3. Cholangiocarcinoma;Brindley;Nat Rev Dis Primers,2021

4. Immunohistology of the pancreas, biliary tract, and liver;Basturk;Diagnostic immunohistochem [Internet],2011

5. Cholangiocarcinoma: a guide for the nonspecialist;Alsaleh;Int J Gen Med,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3